Weekly dose of erlotinib shows decreased duodenal polyp burden and side effects for patients with FAP - Mayo Clinic
Par un écrivain mystérieux
Description
Erlotinib Promising for Cancer Prevention in FAP
KRAS Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Clinical Trial Results National Cancer Institute
NCCN Colon Cancer
International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines - ecancer
Clinical Trial Results National Cancer Institute
Weekly dose of erlotinib shows decreased duodenal polyp burden and side effects for patients with FAP - Mayo Clinic
IJMS, Free Full-Text
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis. - Abstract - Europe PMC
Drug Combo Decreases Colorectal Polyps in People with FAP - NCI
WO2020236562A1 - Methods for treating familial adenomatous polyposis - Google Patents
Collaborative Group of the Americas on Inherited Gastrointestinal Cancers (CGA-IGC) Annual Virtual Meeting, November 13–15, 2021
PDF) Abstract LB-074: Regression of duodenal neoplasia in familial adenomatous polyposis patients using COX and EGFR inhibition: A randomized placebo-controlled trial
Prevention National Cancer Institute
depuis
par adulte (le prix varie selon la taille du groupe)
